Torrent Pharmaceuticals Financials
TORNTPHARM | 3,554 50.20 1.43% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Operating Income | 62.5 B | 59.6 B |
|
|
Torrent | Select Account or Indicator |
Torrent Pharmaceuticals Stock Summary
Torrent Pharmaceuticals competes with Gujarat Lease, Dhunseri Investments, Elgi Rubber, BF Investment, and Styrenix Performance. Torrent Pharmaceuticals is entity of India. It is traded as Stock on NSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | India Stock View All |
Exchange | National Stock Exchange of India |
ISIN | INE685A01028 |
Business Address | Torrent House, Ahmedabad, |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.torrentpharma.com |
Phone | 91 79 2659 9000 |
You should never invest in Torrent Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Torrent Stock, because this is throwing your money away. Analyzing the key information contained in Torrent Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Torrent Pharmaceuticals Key Financial Ratios
Torrent Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Torrent Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Torrent Pharmaceuticals over time and compare it to other companies across industries.Revenue | 115.16 B | ||||
Gross Profit | 87.4 B | ||||
EBITDA | 37.21 B | ||||
Net Income | 19.11 B | ||||
Cash And Equivalents | 2.32 B |
Torrent Pharmaceuticals Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 140.7B | 131.0B | 150.1B | 150.6B | 149.9B | 85.8B | |
Other Current Liab | 8.0B | 7.4B | 1.0B | 8.1B | 10.3B | 5.2B | |
Net Debt | 43.0B | 36.7B | 48.6B | 31.9B | 26.2B | 22.6B | |
Retained Earnings | 28.1B | 29.2B | 33.0B | 39.4B | 76.7B | 80.6B | |
Cash | 5.7B | 4.0B | 5.1B | 8.4B | 5.8B | 4.9B | |
Net Receivables | 18.9B | 19.2B | 19.5B | 18.4B | 18.7B | 12.7B | |
Inventory | 26.8B | 24.6B | 22.3B | 22.8B | 25.4B | 14.0B | |
Other Current Assets | 21.0B | 21.2B | 3.0B | 4.8B | 5.2B | 8.2B | |
Total Liab | 82.4B | 71.5B | 88.1B | 82.0B | 74.0B | 51.5B | |
Total Current Assets | 55.2B | 51.6B | 53.1B | 56.1B | 56.2B | 36.8B | |
Accounts Payable | 20.7B | 16.7B | 16.8B | 20.9B | 18.2B | 15.3B | |
Intangible Assets | 39.8B | 35.5B | 50.9B | 45.8B | 42.6B | 25.2B | |
Short Term Debt | 19.7B | 19.5B | 28.2B | 23.5B | 18.6B | 15.9B | |
Other Liab | 3.2B | 4.3B | 3.8B | 5.7B | 6.6B | 4.2B | |
Net Tangible Assets | (3.6B) | 1.1B | 15.1B | 21.5B | 19.3B | 20.3B | |
Other Assets | 5.3B | 6.8B | 5.4B | 5.8B | 6.2B | 4.3B | |
Long Term Debt | 29.4B | 21.2B | 25.0B | 16.0B | 11.9B | 19.1B | |
Short Long Term Debt | 7.0B | 19.0B | 28.0B | 23.3B | 18.3B | 17.1B | |
Good Will | 3.4B | 2.6B | 3.4B | 3.4B | 3.4B | 3.1B | |
Long Term Debt Total | 29.6B | 21.6B | 25.5B | 16.7B | 13.4B | 20.9B | |
Cash And Equivalents | 149.3M | 228.1M | 379.8M | 4.0B | 2.3B | 2.0B | |
Net Invested Capital | 65.4B | 99.7B | 115.0B | 107.9B | 106.2B | 112.6B |
Torrent Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 3.6B | 2.5B | 3.3B | 3.5B | 2.5B | 1.9B | |
Total Revenue | 78.9B | 84.2B | 94.6B | 106.1B | 115.2B | 120.9B | |
Gross Profit | 56.5B | 58.8B | 67.3B | 46.8B | 57.4B | 35.8B | |
Operating Income | 18.2B | 17.7B | 21.4B | 25.7B | 59.6B | 62.5B | |
Ebit | 18.8B | 14.8B | 21.8B | 27.1B | 29.3B | 30.7B | |
Research Development | 251.8M | 386.5M | 312.7M | 5.3B | 5.8B | 6.1B | |
Ebitda | 25.4B | 21.4B | 28.8B | 35.0B | 37.2B | 39.1B | |
Cost Of Revenue | 22.4B | 25.4B | 27.4B | 59.3B | 27.8B | 17.8B | |
Income Before Tax | 15.3B | 12.3B | 18.5B | 23.5B | 26.7B | 28.1B | |
Net Income | 12.5B | 7.8B | 12.5B | 16.6B | 19.1B | 20.1B | |
Income Tax Expense | 2.7B | 4.5B | 6.0B | 7.0B | 7.6B | 8.0B | |
Tax Provision | 2.7B | 4.5B | 6.0B | 7.0B | 7.6B | 4.6B | |
Interest Income | 3.6B | 2.6B | 3.3B | 114.8M | 2.3B | 2.2B | |
Net Interest Income | (3.6B) | (2.6B) | (3.3B) | (3.5B) | (2.5B) | (2.6B) |
Torrent Pharmaceuticals Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Torrent Pharmaceuticals. It measures of how well Torrent is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Torrent Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Torrent had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Torrent Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | (5.3B) | 2.2B | 2.6B | (490M) | (2.6B) | (2.5B) | |
Change In Cash | (892.6M) | (1.7B) | 1.1B | 3.3B | (2.6B) | (2.5B) | |
Free Cash Flow | 16.8B | 16.0B | 17.9B | 28.3B | 19.7B | 20.7B | |
Depreciation | 6.6B | 6.6B | 7.1B | 8.0B | 8.0B | 8.3B | |
Other Non Cash Items | 1.6B | 2.7B | (1.7B) | 8.1B | 820M | 861M | |
Dividends Paid | 3.4B | 6.8B | 8.6B | 10.2B | 10.8B | 11.4B | |
Capital Expenditures | 3.4B | 2.0B | 5.7B | 4.3B | 6.1B | 3.7B | |
Net Income | 15.3B | 12.3B | 18.5B | 16.6B | 19.1B | 9.6B | |
End Period Cash Flow | 5.7B | 4.0B | 5.1B | 8.4B | 5.7B | 6.7B | |
Investments | (1.2B) | (80.9M) | (24.2B) | (1.7B) | (5.4B) | (5.1B) | |
Net Borrowings | (5.0B) | (3.5B) | (9.6B) | (8.5B) | (7.6B) | (7.2B) | |
Change To Netincome | 6.5B | 1.0B | 4.4B | 7.2B | 8.2B | 8.6B |
Torrent Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Torrent Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Torrent Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Torrent Pharmaceuticals competition to find correlations between indicators driving Torrent Pharmaceuticals's intrinsic value. More Info.Torrent Pharmaceuticals Limited is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.46 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Torrent Pharmaceuticals Limited is roughly 2.17 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Torrent Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Torrent Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Torrent Pharmaceuticals Systematic Risk
Torrent Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Torrent Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Torrent Pharmaceuticals correlated with the market. If Beta is less than 0 Torrent Pharmaceuticals generally moves in the opposite direction as compared to the market. If Torrent Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Torrent Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Torrent Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Torrent Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Torrent Pharmaceuticals Limited Total Assets Over Time
Torrent Pharmaceuticals July 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Torrent Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Torrent Pharmaceuticals Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Torrent Pharmaceuticals Limited based on widely used predictive technical indicators. In general, we focus on analyzing Torrent Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Torrent Pharmaceuticals's daily price indicators and compare them against related drivers.
Downside Deviation | 1.32 | |||
Information Ratio | (0.05) | |||
Maximum Drawdown | 6.17 | |||
Value At Risk | (2.34) | |||
Potential Upside | 2.74 |
Complementary Tools for Torrent Stock analysis
When running Torrent Pharmaceuticals' price analysis, check to measure Torrent Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Torrent Pharmaceuticals is operating at the current time. Most of Torrent Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Torrent Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Torrent Pharmaceuticals' price. Additionally, you may evaluate how the addition of Torrent Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Stocks Directory Find actively traded stocks across global markets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |